

UNITED STATES BANKRUPTCY COURT
DISTRICT OF NEW JERSEY

In re: Immune Pharmaceuticals Inc.
Debtor

Case No. 19-13273
Reporting Period: 8/1/2019 to 8/31/2019

MONTHLY OPERATING REPORT


File with Court and submit copy to United States Trustee within 20 days after end of month.


Submit copy of report to any official committee appointed in the case.

REQUIRED DOCUMENTS	Form No.	Document Attached	Explanation Attached	Affidavit/Supplement Attached
Schedule of Cash Receipts and Disbursements	MOR-1	Yes		
Bank Reconciliation (or copies of debtor's bank reconciliations)	MOR-1a	Yes		
Schedule of Professional Fees Paid	MOR-1b	Yes		
Copies of bank statements		Yes		
Cash disbursements journals		Yes		
Statement of Operations	MOR-2	Yes		
Balance Sheet	MOR-3	Yes		
Status of Postpetition Taxes	MOR-4	N/A		
Copies of IRS Form 6123 or payment receipt				
Copies of tax returns filed during reporting period				
Summary of Unpaid Postpetition Debts	MOR-4	Yes		
Listing of aged accounts payable	MOR-4	Yes		
Accounts Receivable Reconciliation and Aging	MOR-5	Yes		
Debtor Questionnaire	MOR-5	Yes		


I declare under penalty of perjury (28 U.S.C. Section 1746) that this report and the attached documents are true and correct to the best of my knowledge and belief.



Signature of Debtor


Date


Signature of Joint Debtor


Date


Signature of Authorized Individual*


Date


Printed Name of Authorized Individual


Title of Authorized Individual

*Authorized individual must be an officer, director or shareholder if debtor is a corporation, a partner if debtor is a partnership, a manager or member if debtor is a limited liability company.

In re: Immune Pharmaceuticals Inc.
Debtor

Case No. 19-13273
Reporting Period: 8/1/2019 to 8/31/2019

SCHEDULE OF CASH RECEIPTS AND DISBURSEMENTS

Amounts reported should be per the debtor's books, not the bank statement. The beginning cash should be the ending cash from the prior month or, if this is the first report, the amount should be the balance on the date the petition was filed. The amounts reported in the "CURRENT MONTH - ACTUAL" column must equal the sum of the four bank account columns. The amounts reported in the "PROJECTED" columns should be taken from the SMALL BUSINESS INITIAL REPORT (FORM IR-1). Attach copies of the bank statements and the cash disbursements journal. The total disbursements listed in the disbursements journal must equal the total disbursements reported on this page. A bank reconciliation must be attached for each account. [See MOR-1 (CONT)]

	BANK ACCOUNTS			CURRENT MONTH		CUMULATIVE FILING TO DATE	
	OPER.	PAYROLL	TAX	DIP	ACTUAL	PROJECTED	ACTUAL
CASH BEGINNING OF MONTH		0.00			1,987.78	1,987.78	
RECEIPTS							
RENT AND ADDITIONAL TENANT REIMBURSEMENTS/PAYMENTS					0.00		0.00
ACCOUNTS RECEIVABLE				0.00	0.00		105,023.29
LOANS AND ADVANCES					0.00		0.00
SALE OF ASSETS					0.00		0.00
OTHER (ATTACH LIST)					0.00		81.86
TRANSFERS (FROM DIP ACCTS)					0.00		8,969.23
TRANSFERS FROM RELATED CO'S					0.00		0.00
TOTAL RECEIPTS		\$0.00		\$0.00	\$0.00		\$114,074.38
DISBURSEMENTS							
NET PAYROLL				0.00	0.00		122,555.56
PAYROLL TAXES					0.00		0.00
SALES, USE, & OTHER TAXES					0.00		0.00
INVENTORY PURCHASES					0.00		0.00
SECURED/ RENTAL/ LEASES					0.00		0.00
INSURANCE					0.00		0.00
ADMINISTRATIVE				1,385.85	1,385.85		12,567.09
SELLING					0.00		0.00
OTHER (ATTACH LIST)					0.00		0.00
					0.00		0.00
OWNER DRAW *					0.00		0.00
TRANSFERS (TO DIP ACCTS)					0.00		714.23
TRANSFERS TO RELATED CO'S					0.00		0.00
PROFESSIONAL FEES					0.00		0.00
U.S. TRUSTEE QUARTERLY FEES				0.00	0.00		0.00
COURT COSTS					0.00		0.00
TOTAL DISBURSEMENTS		\$0.00		\$1,385.85	\$1,385.85		\$135,836.88
NET CASH FLOW		0.00		(1,385.85)	(1,385.85)		(21,762.50)
(RECEIPTS LESS DISBURSEMENTS)							
CASH - END OF MONTH		\$0.00		\$601.93	\$601.93		(\$20,648.27)

* COMPENSATION TO SOLE PROPRIETORS FOR SERVICES RENDERED TO BANKRUPTCY ESTATE

THE FOLLOWING SECTION MUST BE COMPLETED

DISBURSEMENTS FOR CALCULATING U.S. TRUSTEE QUARTERLY FEES: (FROM CURRENT MONTH ACTUAL COLUMN)		
TOTAL DISBURSEMENTS		\$1,385.85
LESS: TRANSFERS TO DEBTOR IN POSSESSION ACCOUNTS		\$0.00
PLUS: ESTATE DISBURSEMENTS MADE BY OUTSIDE SOURCES (i.e. from escrow accounts)		\$0.00
TOTAL DISBURSEMENTS FOR CALCULATING U.S. TRUSTEE QUARTERLY FEES		\$1,385.85

**In re: Immune Pharmaceuticals Inc.
Debtor**

Case No. 19-13273
Reporting Period: 8/1/2019 to 8/31/2019

BANK RECONCILIATIONS

Continuation Sheet for MOR-1

A bank reconciliation must be included for each bank account. The debtor's bank reconciliation may be substituted for this page.

**In re: Immune Pharmaceuticals Inc.
Debtor**

Case No. 19-13273

SCHEDULE OF PROFESSIONAL FEES AND EXPENSES PAID

This schedule is to include all retained professional payments from case inception to current month.



E STATEMENT OF ACCOUNT

IMMUNE PHARMACEUTICALS INC DIP
PO BOX 337
MIDDLETOWN NJ 07748-0337

Page: 1 of 3
Statement Period: Sep 01 2019-Sep 30 2019
Cust Ref #: 4354160354-717-E***
Primary Account #: [REDACTED]

TD now accepts Real Time Payments!

We're pleased to announce that TD will soon accept Real Time Payments (RTPs), which means you can receive certain electronic payments sent through RTP almost immediately. This is good news for consumers, businesses, and government agencies who use RTPs. As a TD Customer, you are automatically enrolled. Please be advised that you may not send or receive RTPs on behalf of a person who is not a resident of, or otherwise residing in, the United States. Please visit tdbank.com/RTP to learn more.

TD Business Convenience Plus

IMMUNE PHARMACEUTICALS INC DIP

Account # [REDACTED]

ACCOUNT SUMMARY

Beginning Balance	601.93	Average Collected Balance	225.29
Electronic Payments	537.56	Interest Earned This Period	0.00
Service Charges	25.00	Interest Paid Year-to-Date	0.00
Ending Balance	39.37	Annual Percentage Yield Earned	0.00%
		Days in Period	30

DAILY ACCOUNT ACTIVITY

Electronic Payments

POSTING DATE	DESCRIPTION	AMOUNT
09/03	DEBIT CARD PURCHASE, AUT 082919 VISA DDA PUR SPECTRUM 888 TWCABLE * CA 4085404022953131	179.45
09/03	DEBIT CARD PURCHASE, AUT 090119 VISA DDA PUR GOOGLE GSUITE CYTOVIA CC GOOGLE COM * CA 4085404022953131	54.00
09/03	DEBIT CARD PURCHASE, AUT 083019 VISA DDA PUR UBER EATS HELP UBER COM * CA 4085404022953131	30.96
09/03	DEBIT CARD PURCHASE, AUT 083019 VISA DDA PUR UBER TRIP HELP UBER COM * CA 4085404022953131	8.23
09/03	DEBIT CARD PURCHASE, AUT 083019 VISA DDA PUR UBER TRIP HELP UBER COM * CA 4085404022953131	7.53
09/03	DEBIT CARD PURCHASE, AUT 083019 VISA DDA PUR UBER TRIP HELP UBER COM * CA 4085404022953131	6.46
09/16	DEBIT CARD PURCHASE, AUT 091519 VISA DDA PUR VZWRLLS PREPAID PYMTN 888 294 6804 * FL 4085404022953131	31.99
09/16	DEBIT CARD PURCHASE, AUT 091419 VISA DDA PUR DAGWOODS PIZZA ECOM 310 899 3030 * CA 4085404022953131	18.00

Call 1-800-937-2000 for 24-hour Bank-by-Phone services or connect to www.tdbank.com

Bank Deposits FDIC Insured | TD Bank, N.A. | Equal Housing Lender [REDACTED]



America's Most Convenient Bank®

STATEMENT OF ACCOUNT

IMMUNE PHARMACEUTICALS INC DIP

Page: 3 of 3
Statement Period: May 01 2019-May 31 2019
Cust Ref #: 4354160354-717-E***
Primary Account #: [REDACTED]

DAILY ACCOUNT ACTIVITY

Electronic Payments (continued)

POSTING DATE	DESCRIPTION	AMOUNT
05/20	DEBIT CARD PAYMENT, AUT 051819 VISA DDA PUR MSFT E08008CFCU 800 642 7676 * WA 4085404022953131	45.00
05/20	DEBIT CARD PAYMENT, AUT 051819 VISA DDA PUR MSFT E08008CFCU 800 642 7676 * WA 4085404022953131	12.00
05/21	DEBIT CARD PAYMENT, AUT 052019 VISA DDA PUR PANTHEON SYSTEMS INC HTTPS-PANTHEON * CA 4085404022953131	35.00
05/22	ELECTRONIC PMT-WEB, VERIZON VZ BILLPAY 9557656840001	169.52
	Subtotal:	3,493.21

Other Withdrawals

POSTING DATE	DESCRIPTION	AMOUNT
05/20	WIRE TRANSFER OUTGOING, Donna Rabin	4,000.00
05/20	WIRE TRANSFER FEE	25.00
	Subtotal:	4,025.00

Service Charges

POSTING DATE	DESCRIPTION	AMOUNT
05/31	MAINTENANCE FEE	25.00
	Subtotal:	25.00

DAILY BALANCE SUMMARY

DATE	BALANCE	DATE	BALANCE
04/30	8,763.47	05/17	5,531.78
05/10	7,668.16	05/20	1,449.78
05/14	5,684.83	05/21	1,414.78
05/15	5,593.78	05/22	1,245.26
05/16	5,563.77	05/31	1,220.26

In re: Immune Pharmaceuticals Inc.
Debtor

Case No. 19-13273
Reporting Period: 8/1/2019 to 8/31/2019

Cash Disbursements Journal

In re: Immune Pharmaceuticals Inc.
Debtor

Case No. 19-13273
Reporting Period: 8/1/2019 to 8/31/2019

STATEMENT OF OPERATIONS
(Income Statement)

The Statement of Operations is to be prepared on an accrual basis. The accrual basis of accounting recognizes revenue when it is realized and expenses when they are incurred, regardless of when cash is actually received or paid.

INCOME	Month	Cumulative Filing to Date
License Revenue	0.00	105,000.00
		0.00
		0.00
Total Income	0.00	105,000.00
EXPENSES		
R&D - Clinical Trials	0.00	70,892.42
G&A - Compensation		0.00
G&A - Compensation other		0.00
		0.00
Insider Compensation*	38,332.00	250,426.86
Insurance	0.00	47,391.33
G&A - IT	186.61	4,912.93
G&A - Compliance	0.00	9,539.00
Repairs		0.00
Supplies	0.00	349.61
Travel and Entertainment	1,360.85	8,538.31
Rent	0.00	31,308.71
Utilities	31.99	1,797.49
Other: (List Below)		0.00
Storage	1,346.88	6,304.61
Business/sale development	0.00	31,061.49
Bank fees	25.00	373.50
Total Operating Expenses Before Depreciation	41,283.33	462,896.26
Depreciation/Depletion/Amortization		
Net Income (Loss) Before Other Income & Expenses	\$ (41,283.33)	\$ (357,896.26)
OTHER INCOME AND EXPENSES		
Other Income: (List Below)		0.00
Miscellaneous		81.86
		0.00
		0.00
Interest Expense		0.00
Other Expense: (List Below)		0.00
		0.00
		0.00
		0.00
Net Income (Loss) Before Reorganization Items	(41,283.33)	(357,814.40)
REORGANIZATION ITEMS		
Professional Fees	0.00	0.00
U. S. Trustee Quarterly Fees	0.00	325.00
Interest Earned on Accumulated Cash from Chapter 11**		0.00
Gain (Loss) from Sale of Property		0.00
Other Reorganization Expense: (List Below)		0.00
		0.00
		0.00
		0.00
Total Reorganization Expenses	0.00	325.00
Income Taxes		
Net Income (Loss)	\$ (41,283.33)	\$ (358,139.40)

*"Insider" is defined in 11 U.S.C. Section 101(31).

**Interest Earned on Accumulated Cash from Chapter 11: Interest earned on cash accumulated during the chapter 11 case, which would not have been earned but for the bankruptcy proceeding, should be reported as a reorganization item.

In re: Immune Pharmaceuticals Inc.
Debtor

Case No. 19-13273
Reporting Period: 8/1/2019 to 8/31/2019

STATEMENT OF OPERATIONS - continuation sheet

BREAKDOWN OF "OTHER" CATEGORY	Month	Cumulative Filing to Date
Other Costs		
Other Operational Expenses		
Other Income		
Other Expenses		
Other Reorganization Expenses		

Reorganization Items - Interest Earned on Accumulated Cash from Chapter 11:

Interest earned on cash accumulated during the chapter 11 case, which would not have been earned but for the bankruptcy proceeding, should be reported as a reorganization item.

In re: Immune Pharmaceuticals Inc.
Debtor

Case No. 19-13273
Reporting Period: 8/1/2019 to 8/31/2019

BALANCE SHEET

The Balance Sheet is to be completed on an accrual basis only. Pre-petition liabilities must be classified separately from postpetition obligations.

ASSETS	BOOK VALUE AT END OF CURRENT REPORTING MONTH	BOOK VALUE ON PETITION DATE
CURRENT ASSETS		
Unrestricted Cash and Equivalents	601.93	1,114.23
Restricted Cash and Cash Equivalents (see continuation sheet)		
Accounts Receivable (Net)		
Notes Receivable		
Inventories		
Prepaid Expenses	80,641.85	80,641.85
Professional Retainers		
Other Current Assets (attach schedule)	0.00	0.00
TOTAL CURRENT ASSETS	81,243.78	81,756.08
PROPERTY AND EQUIPMENT		
Real Property and Improvements (value based on tax assessment - subject to dispute)		
Machinery and Equipment		
Furniture, Fixtures and Office Equipment	55,218.58	55,218.58
Leasehold Improvements		
Vehicles		
Less Accumulated Depreciation		
TOTAL PROPERTY & EQUIPMENT	55,218.58	55,218.58
OTHER ASSETS		
Loans to Insiders*		
Other Assets (attach schedule)	21,014,915.06	21,034,232.76
TOTAL OTHER ASSETS	\$21,014,915.06	\$21,034,232.76
TOTAL ASSETS	\$21,151,377.42	\$21,171,207.42

LIABILITIES AND OWNER EQUITY	BOOK VALUE AT END OF CURRENT REPORTING MONTH	BOOK VALUE ON PETITION DATE
LIABILITIES NOT SUBJECT TO COMPROMISE (Postpetition)		
Accounts Payable		
Taxes Payable (refer to FORM MOR-4)		
Wages Payable		
Notes Payable		
Rent / Leases - Building/Equipment		
Secured Debt / Adequate Protection Payments		
Professional Fees		
Amounts Due to Insiders*	260,563.33	
Other Postpetition Liabilities (attach schedule)		
TOTAL POSTPETITION LIABILITIES	260,563.33	0.00
LIABILITIES SUBJECT TO COMPROMISE (Pre-Petition)		
Secured Debt**	2,200,000.00	2,200,000.00
Accounts Payable	61,900.97	
Priority Debt	3,651,480.00	3,651,480.00
Unsecured Debt	9,910,959.30	9,910,959.30
TOTAL PRE-PETITION LIABILITIES	\$15,824,340.27	\$15,762,439.30
TOTAL LIABILITIES	\$16,084,903.60	\$15,762,439.30
OWNER EQUITY		
Capital Stock	7,238.33	7,238.33
Additional Paid-In Capital	101,389,628.54	101,389,628.54
Partners' Capital Account		
Owner's Equity Account		
Retained Earnings - Pre-Petition	-\$95,988,098.75	-\$95,988,098.75
Retained Earnings - Postpetition	-\$342,294.30	0
Adjustments to Owner Equity (attach schedule)		
Postpetition Contributions (Distributions) (Draws) (attach schedule)		
NET OWNER EQUITY	\$ 5,066,473.82	\$ 5,408,768.12
TOTAL LIABILITIES AND OWNERS' EQUITY	\$21,151,377.42	\$21,171,207.42

*"Insider" is defined in 11 U.S.C. Section 101(31).

**The secured debt is the alleged secured claim of Discover, which is disputed and the subject of a pending adversary proceeding.

In re: Immune Pharmaceuticals Inc.
Debtor

Case No. 19-13273

BALANCE SHEET - continuation sheet

Restricted Cash is cash that is restricted for a specific use and not available to fund operations. Typically, restricted cash is segregated into a separate account, such as an escrow account.

In re: Immune Pharmaceuticals Inc.
Debtor

Case No. 19-13273
Reporting Period: 8/1/2019 to 8/31/2019

STATUS OF POSTPETITION TAXES

The beginning tax liability should be the ending liability from the prior month or, if this is the first report, the amount should be zero.

Attach photocopies of IRS Form 6123 or payment receipt to verify payment or deposit of federal payroll taxes.

Attach photocopies of any tax returns filed during the reporting period.

	Beginning Tax Liability	Amount Withheld or Accrued	Amount Paid	Date Paid	Check No. or EFT	Ending Tax Liability
Federal						
Withholding						
FICA-Employee						
FICA-Employer						
Unemployment						
Income						
Other:						
Total Federal Taxes						
State and Local						
Withholding						
Sales						
Excise						
Unemployment						
Real Property						
Personal Property						
Other:						
Total State and Local						
Total Taxes	0.00	0.00	0.00		0.00	0.00

SUMMARY OF UNPAID POSTPETITION DEBTS

Attach aged listing of accounts payable.

	Number of Days Past Due					Total
	Current	0-30	31-60	61-90	Over 90	
Accounts Payable	3,860.00	3,881.00	8,484.00	21,310.00	138,595.00	176,130.00
Wages Payable						0.00
Taxes Payable						0.00
Rent/Leases-Building						0.00
Rent/Leases-Equipment						0.00
Secured Debt/Adequate Protection Payments						0.00
Professional Fees						0.00
Amounts Due to Insiders*	38,332.00	55,209.00	55,209.66	43,310.00	68,502.67	260,563.33
Other:						0.00
Other:						0.00
Total Postpetition Debts	42,192.00	59,090.00	63,693.66	64,620.00	207,097.67	436,693.33

Explain how and when the Debtor intends to pay any past-due postpetition debts.

*"Insider" is defined in 11 U.S.C. Section 101(31).

In re: Immune Pharmaceuticals Inc.
Debtor

Case No. 19-13273
Reporting Period: 8/1/2019 to 8/31/2019

Listing of Aged Accounts Payable

Monthly Aged Payables

In re: Immune Pharmaceuticals Inc.
Debtor

Case No. 19-13273
Reporting Period: 8/1/2019 to 8/31/2019

ACCOUNTS RECEIVABLE RECONCILIATION AND AGING

Accounts Receivable Reconciliation	Amount
Total Accounts Receivable at the beginning of the reporting period	\$0.00
+ Amounts billed during the period	\$0.00
- Amounts collected during the period	
Total Accounts Receivable at the end of the reporting period	\$0.00

Accounts Receivable Aging	Amount
0 - 30 days old	\$0.00
31 - 60 days old	\$0.00
61 - 90 days old	\$0.00
91+ days old	\$0.00
Total Accounts Receivable	\$0.00
Amount considered uncollectible (Bad Debt)	0
Accounts Receivable (Net)	\$0.00

DEBTOR QUESTIONNAIRE

Must be completed each month	Yes	No
1. Have any assets been sold or transferred outside the normal course of business this reporting period? If yes, provide an explanation below.		X
2. Have any funds been disbursed from any account other than a debtor in possession account this reporting period? If yes, provide an explanation below.		X
3. Have all postpetition tax returns been timely filed? If no, provide an explanation below.	X	
4. Are workers compensation, general liability and other necessary insurance coverages in effect? If no, provide an explanation below.	X	
5. Has any bank account been opened during the reporting period? If yes, provide documentation identifying the opened account(s). If an investment account has been opened provide the required documentation pursuant to the Delaware Local Rule 4001-3.		X